The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunityCad1 is an hexameric type III CRISPR-CARF effector harboring an adenosine deaminase domain that is activated by cyclic oligonucleotides produced upon phage recognition. Cad1 activation results in ATP deamination, accumulation of ITP, and a growth arrest of the infected host that prevents viral spread.Cad1 is an hexameric type III CRISPR-CARF effector harboring an adenosine deaminase domain that is activated by cyclic oligonucleotides produced upon phage recognition. Cad1 activation results in ATP deamination, accumulation of ITP, and a growth arrest of the infected host that prevents viral spread.Christian F. Baca, Puja Majumder, James H. Hickling, Linzhi Ye, Marianna Teplova, Sean F. Brady, Dinshaw J. Patel, Luciano A. Marraffinihttps://www.cell.com/cell/fulltext/S0092-8674(24)01150-4?rss=yeshttp://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignOctober 29, 2024

Powered by WPeMatico